Cardio-Oncology Rehabilitation to Manage Cardiovascular Outcomes in Cancer Patients and Survivors: A Scientific Statement From the American Heart Association.

Published

Journal Article

Cardiovascular disease is a competing cause of death in patients with cancer with early-stage disease. This elevated cardiovascular disease risk is thought to derive from both the direct effects of cancer therapies and the accumulation of risk factors such as hypertension, weight gain, cigarette smoking, and loss of cardiorespiratory fitness. Effective and viable strategies are needed to mitigate cardiovascular disease risk in this population; a multimodal model such as cardiac rehabilitation may be a potential solution. This statement from the American Heart Association provides an overview of the existing knowledge and rationale for the use of cardiac rehabilitation to provide structured exercise and ancillary services to cancer patients and survivors. This document introduces the concept of cardio-oncology rehabilitation, which includes identification of patients with cancer at high risk for cardiac dysfunction and a description of the cardiac rehabilitation infrastructure needed to address the unique exposures and complications related to cancer care. In this statement, we also discuss the need for future research to fully implement a multimodal model of cardiac rehabilitation for patients with cancer and to determine whether reimbursement of these services is clinically warranted.

Full Text

Duke Authors

Cited Authors

  • Gilchrist, SC; Barac, A; Ades, PA; Alfano, CM; Franklin, BA; Jones, LW; La Gerche, A; Ligibel, JA; Lopez, G; Madan, K; Oeffinger, KC; Salamone, J; Scott, JM; Squires, RW; Thomas, RJ; Treat-Jacobson, DJ; Wright, JS; American Heart Association Exercise, Cardiac Rehabilitation, and Secondary Prevention Committee of the Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; and Council on Peripheral Vascular Disease,

Published Date

  • May 21, 2019

Published In

Volume / Issue

  • 139 / 21

Start / End Page

  • e997 - e1012

PubMed ID

  • 30955352

Pubmed Central ID

  • 30955352

Electronic International Standard Serial Number (EISSN)

  • 1524-4539

Digital Object Identifier (DOI)

  • 10.1161/CIR.0000000000000679

Language

  • eng

Conference Location

  • United States